# Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

> **NCT01003106** · PHASE1,PHASE2 · COMPLETED · sponsor: **Peter A Campochiaro, MD** · enrollment: 81 (actual)

## Conditions studied

- Retinal Vein Occlusion

## Interventions

- **DRUG:** Ranibizumab 0.5mg (monthly)
- **DRUG:** Ranibizumab 2.0mg (monthly)
- **DRUG:** Pro re nata (prn) ranibizumab
- **PROCEDURE:** Pro re nata (prn) Laser photocoagulation

## Key facts

- **NCT ID:** NCT01003106
- **Lead sponsor:** Peter A Campochiaro, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2016-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01003106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01003106, "Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01003106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*